Antibody engineering to battle cancer
Merus has raised €126M across 3 funding rounds from 5 investors, most recently a Series C round in Aug 2015. Based in Utrecht, Netherlands; founded 2003; active in Healthtech. Acquired by Genmab in 2025. Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2015-08-01 | Series C | €73M | Life Sciences Partners,Novartis Venture Fund,Novo A,S,Sofinnova Partners | View deal → |
| 2013-10-01 | Series B |
| €31M |
| Life Sciences Partners,Novartis Venture Fund |
| View deal → |
| 2007-01-01 | Series A | €22M | Life Sciences Partners,Novartis Venture Fund | View deal → |
